PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 228 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $11,444,052 | -1.6% | 400,002 | +0.5% | 0.00% | 0.0% |
Q1 2024 | $11,625,494 | -19.0% | 397,861 | -6.4% | 0.00% | -33.3% |
Q4 2023 | $14,346,890 | +3.1% | 425,219 | -6.3% | 0.00% | 0.0% |
Q3 2023 | $13,920,775 | -26.2% | 453,741 | -3.6% | 0.00% | -25.0% |
Q2 2023 | $18,857,543 | -4.2% | 470,615 | -2.5% | 0.00% | 0.0% |
Q1 2023 | $19,690,622 | +9.1% | 482,495 | +3.2% | 0.00% | 0.0% |
Q4 2022 | $18,052,221 | -29.8% | 467,553 | -3.4% | 0.00% | -33.3% |
Q3 2022 | $25,731,000 | -7.0% | 483,768 | +1.9% | 0.01% | 0.0% |
Q2 2022 | $27,681,000 | -29.3% | 474,766 | -7.4% | 0.01% | -25.0% |
Q1 2022 | $39,148,000 | +30.9% | 512,945 | +3.2% | 0.01% | +60.0% |
Q4 2021 | $29,903,000 | +11.7% | 496,985 | +3.9% | 0.01% | 0.0% |
Q3 2021 | $26,777,000 | -6.6% | 478,160 | +1.2% | 0.01% | -16.7% |
Q2 2021 | $28,683,000 | -15.3% | 472,688 | -2.2% | 0.01% | -14.3% |
Q1 2021 | $33,876,000 | +16.5% | 483,317 | -0.5% | 0.01% | +16.7% |
Q4 2020 | $29,068,000 | -5.6% | 485,769 | -5.2% | 0.01% | -25.0% |
Q3 2020 | $30,804,000 | +12.1% | 512,370 | -2.2% | 0.01% | +14.3% |
Q2 2020 | $27,475,000 | +66.8% | 523,631 | +6.6% | 0.01% | +40.0% |
Q1 2020 | $16,471,000 | -27.2% | 491,236 | -1.6% | 0.01% | -16.7% |
Q4 2019 | $22,616,000 | +20.5% | 499,260 | +1.3% | 0.01% | +20.0% |
Q3 2019 | $18,765,000 | +102.8% | 492,877 | +131.7% | 0.01% | +66.7% |
Q2 2019 | $9,251,000 | +11.1% | 212,712 | -2.7% | 0.00% | +50.0% |
Q1 2019 | $8,323,000 | -8.0% | 218,698 | +4.0% | 0.00% | -33.3% |
Q4 2018 | $9,049,000 | -17.1% | 210,336 | -5.2% | 0.00% | 0.0% |
Q3 2018 | $10,911,000 | +53.1% | 221,982 | -0.1% | 0.00% | +50.0% |
Q2 2018 | $7,125,000 | +1.2% | 222,286 | -1.7% | 0.00% | 0.0% |
Q1 2018 | $7,043,000 | -30.9% | 226,075 | +1.3% | 0.00% | -33.3% |
Q4 2017 | $10,187,000 | +14.9% | 223,157 | -5.5% | 0.00% | +50.0% |
Q3 2017 | $8,865,000 | -14.8% | 236,058 | +8.2% | 0.00% | -33.3% |
Q2 2017 | $10,403,000 | +10.5% | 218,087 | +5.6% | 0.00% | 0.0% |
Q1 2017 | $9,415,000 | +47.2% | 206,435 | +4.2% | 0.00% | +50.0% |
Q4 2016 | $6,398,000 | -1.5% | 198,069 | +4.4% | 0.00% | 0.0% |
Q3 2016 | $6,494,000 | +5.3% | 189,761 | +3.8% | 0.00% | 0.0% |
Q2 2016 | $6,166,000 | -42.1% | 182,835 | -9.1% | 0.00% | -33.3% |
Q1 2016 | $10,653,000 | -38.8% | 201,069 | -11.3% | 0.00% | -40.0% |
Q4 2015 | $17,400,000 | +117.9% | 226,609 | +16.7% | 0.01% | +150.0% |
Q3 2015 | $7,984,000 | -48.9% | 194,254 | -12.1% | 0.00% | -50.0% |
Q2 2015 | $15,621,000 | -55.7% | 220,891 | -44.4% | 0.00% | -55.6% |
Q1 2015 | $35,280,000 | -34.9% | 397,083 | -35.1% | 0.01% | -35.7% |
Q4 2014 | $54,232,000 | +159.8% | 611,689 | +184.0% | 0.01% | +133.3% |
Q3 2014 | $20,874,000 | -75.6% | 215,389 | -76.9% | 0.01% | -50.0% |
Q2 2014 | $85,506,000 | +151.2% | 930,836 | +91.4% | 0.01% | +33.3% |
Q1 2014 | $34,033,000 | -38.7% | 486,260 | -49.6% | 0.01% | -40.0% |
Q4 2013 | $55,475,000 | +71.6% | 964,950 | +43.5% | 0.02% | +200.0% |
Q3 2013 | $32,326,000 | +700.3% | 672,452 | +382.8% | 0.01% | +400.0% |
Q2 2013 | $4,039,000 | – | 139,282 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tamarack Advisers, LP | 273,000 | $8,818,000 | 6.24% |
Standard Investments LLC | 775,388 | $25,045,000 | 4.58% |
ARMISTICE CAPITAL, LLC | 400,000 | $12,920,000 | 3.06% |
HealthCor Management, L.P. | 1,575,000 | $50,873,000 | 2.88% |
DARUMA CAPITAL MANAGEMENT LLC | 1,219,642 | $39,394,000 | 2.24% |
Consonance Capital Management LP | 631,805 | $20,407,000 | 2.24% |
Rock Springs Capital Management LP | 713,000 | $23,030,000 | 1.54% |
Biondo Investment Advisors, LLC | 142,473 | $4,602,000 | 1.52% |
Opus Point Partners Management, LLC | 50,000 | $1,615,000 | 1.29% |
Partner Investment Management, L.P. | 26,690 | $862,000 | 1.14% |